NASDAQ:ASLN ASLAN Pharmaceuticals (ASLN) Stock Price, News & Analysis $2.15 -0.23 (-9.66%) (As of 12:07 PM ET) Add Compare Share Share Today's Range$2.08▼$2.3750-Day Range$2.25▼$3.9952-Week Range$2.08▼$28.00Volume21,777 shsAverage Volume87,668 shsMarket Capitalization$4.39 millionP/E RatioN/ADividend YieldN/APrice Target$90.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get ASLAN Pharmaceuticals alerts: Email Address ASLAN Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside4,117.1% Upside$90.67 Price TargetShort InterestHealthy1.24% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($20.36) to ($18.80) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.03 out of 5 stars 3.5 Analyst's Opinion Consensus RatingASLAN Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageASLAN Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about ASLAN Pharmaceuticals' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.24% of the float of ASLAN Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverASLAN Pharmaceuticals has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ASLAN Pharmaceuticals has recently decreased by 9.25%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldASLAN Pharmaceuticals does not currently pay a dividend.Dividend GrowthASLAN Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ASLN. Previous Next 0.6 News and Social Media Coverage Search Interest14 people have searched for ASLN on MarketBeat in the last 30 days. MarketBeat FollowsOnly 2 people have added ASLAN Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ASLAN Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.69% of the stock of ASLAN Pharmaceuticals is held by insiders.Percentage Held by Institutions58.82% of the stock of ASLAN Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ASLAN Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ASLAN Pharmaceuticals are expected to grow in the coming year, from ($20.36) to ($18.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ASLAN Pharmaceuticals is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ASLAN Pharmaceuticals is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about ASLAN Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Oasis GoldNew Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of opportunity to protect your interests is closing fast.Click Here To Get Your FREE Guide Now! About ASLAN Pharmaceuticals Stock (NASDAQ:ASLN)ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.Read More ASLN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ASLN Stock News HeadlinesJune 25, 2024 | americanbankingnews.comASLAN Pharmaceuticals Stock Set to Reverse Split on Wednesday, July 3rd (NASDAQ:ASLN)May 21, 2024 | globenewswire.comASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Eblasakimab in COPD at the American Thoracic Society International ConferenceJuly 5, 2024 | Awesomely, LLC (Ad)Automatic Income (from home)Everyone’s talking about this new income hack that could generate triple digit returns on your money. But here’s the best part…May 9, 2024 | globenewswire.comASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 7, 2024 | globenewswire.comASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL EventMay 2, 2024 | globenewswire.comASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other BiologicsApril 30, 2024 | globenewswire.comASLAN Pharmaceuticals to Host KOL Panel Discussion on Treatment Options for Atopic Dermatitis Patients With an Inadequate Response to DupilumabApril 24, 2024 | finance.yahoo.comASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for Presentation at the American Thoracic Society International ConferenceJuly 5, 2024 | Awesomely, LLC (Ad)Automatic Income (from home)Everyone’s talking about this new income hack that could generate triple digit returns on your money. But here’s the best part…April 22, 2024 | markets.businessinsider.comAslan Announces Positive Results For Phase 2 Study Of Eblasakimab In AD PatientsApril 22, 2024 | globenewswire.comASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis PatientsApril 20, 2024 | finanznachrichten.deASLAN PHARMACEUTICALS LIMITED: ASLAN Pharmaceuticals Announces Receipt of Nasdaq NoticeApril 19, 2024 | globenewswire.comASLAN Pharmaceuticals Announces Receipt of Nasdaq NoticeApril 14, 2024 | finanznachrichten.deASLAN PHARMACEUTICALS LIMITED: ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateApril 12, 2024 | msn.comASLAN Falls On Q4 FiguresApril 12, 2024 | markets.businessinsider.comASLN Stock Earnings: ASLAN Pharma Misses EPS for Q4 2023April 12, 2024 | globenewswire.comASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 27, 2024 | globenewswire.comAslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and DisordersSee More Headlines Receive ASLN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ASLAN Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/05/2024Next Earnings (Estimated)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ASLN CUSIPN/A CIK1722926 Webwww.aslanpharma.com Phone65-6817-9598Fax65-6225-2419Employees35Year FoundedN/APrice Target and Rating Average Stock Price Target$90.67 High Stock Price Target$120.00 Low Stock Price Target$72.00 Potential Upside/Downside+3,825.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-44,220,000.00 Net MarginsN/A Pretax Margin-290.83% Return on Equity-8,454.87% Return on Assets-121.60% Debt Debt-to-Equity RatioN/A Current Ratio1.05 Quick Ratio1.05 Sales & Book Value Annual Sales$12 million Price / Sales0.39 Cash FlowN/A Price / Cash FlowN/A Book Value($6.50) per share Price / Book-0.36Miscellaneous Outstanding Shares2,040,000Free Float15,583,000Market Cap$4.71 million OptionableOptionable Beta1.40 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Carl Alan Jason Morton Firth EMBA (Age 51)Ph.D., Founder, CEO & Executive Director Mr. Kiran Kumar Asarpota (Age 45)COO & Head of Finance Mr. Ben Goodger (Age 61)General Counsel Mr. Stephen Doyle (Age 51)Chief Business Officer Dr. Alexandre Kaoukhov M.D. (Age 50)Chief Medical Officer Charlie HsuInvestor Relations DirectorChi-Chin WangIR & Corporate Development DirectorMore ExecutivesKey CompetitorsJanOneNASDAQ:JANUnicycive TherapeuticsNASDAQ:UNCYIterum TherapeuticsNASDAQ:ITRMGlycoMimeticsNASDAQ:GLYCApollomicsNASDAQ:APLMView All Competitors ASLN Stock Analysis - Frequently Asked Questions How have ASLN shares performed this year? ASLAN Pharmaceuticals' stock was trading at $4.1768 on January 1st, 2024. Since then, ASLN stock has decreased by 48.5% and is now trading at $2.15. View the best growth stocks for 2024 here. How were ASLAN Pharmaceuticals' earnings last quarter? ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) released its quarterly earnings results on Thursday, May, 9th. The company reported ($10.32) EPS for the quarter, missing the consensus estimate of ($5.44) by $4.88. When did ASLAN Pharmaceuticals' stock split? ASLAN Pharmaceuticals shares reverse split on Wednesday, July 3rd 2024. The 1-8 reverse split was announced on Wednesday, July 3rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 3rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. When did ASLAN Pharmaceuticals IPO? ASLAN Pharmaceuticals (ASLN) raised $60 million in an initial public offering (IPO) on Friday, May 4th 2018. The company issued 7,500,000 shares at $8.05 per share. Leerink Partners and Piper Jaffray acted as the underwriters for the IPO and BTIG, H.C. Wainwright and CLSA were co-managers. How do I buy shares of ASLAN Pharmaceuticals? Shares of ASLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of ASLAN Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that ASLAN Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Arbutus Biopharma (ABUS), Allena Pharmaceuticals (ALNA), Actinium Pharmaceuticals (ATNM), Inovio Pharmaceuticals (INO), OPKO Health (OPK) and Onconova Therapeutics (ONTX). This page (NASDAQ:ASLN) was last updated on 7/5/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored50-year Wall Street Legend: “Prepare for a cash avalanche”The Dow crossed 40,000 for the first time in history… The S&P has hit over 30 all-time highs since the star...Chaikin Analytics | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredNew Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ASLAN Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share ASLAN Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.